Blood‐based biomarkers for Alzheimer's disease
Progress in Neurology and Psychiatry · 2022-10 · 26 (4) · 10-14
DOI: 10.1002/pnp.764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Progress in Neurology and Psychiatry, online erschienen am 08.11.2022. Verfasst von Priyanka Chohan und 4 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Blood‐based biomarkers for identifying Alzheimer's disease (AD) pathology have been of considerable interest over the past decade and can offer a significant advantage over the currently available and validated cerebrospinal fluid and positron emission tomography biomarkers in terms of cost, invasiveness and accessibility. This review explores the role of three blood‐based biomarkers; plasma amyloid β, tau and neurofilament light chain, and their combination, in the identification of AD pathology and how they may be utilised in clinical practice.
Zitieren
APA
Chohan, P., Dashwood, M., Theodoulou, G., Reed, H., & Kuruvilla, T. (2022). Blood‐based biomarkers for Alzheimer's disease. Progress in Neurology and Psychiatry, 26(4), 10-14. https://doi.org/10.1002/pnp.764
Vancouver
Chohan P, Dashwood M, Theodoulou G, Reed H, Kuruvilla T. Blood‐based biomarkers for Alzheimer's disease. Progress in Neurology and Psychiatry. 2022;26(4):10-14. doi:10.1002/pnp.764
BibTeX
@article{Chohan2022,
author = {Chohan, Priyanka and Dashwood, Mark and Theodoulou, George and Reed, Hannah and Kuruvilla, Tarun},
title = {Blood‐based biomarkers for Alzheimer's disease},
journal = {Progress in Neurology and Psychiatry},
year = {2022},
volume = {26},
number = {4},
pages = {10--14},
doi = {10.1002/pnp.764}
}
EUVIMED